Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin: 2022-2025

Historic EBITDA Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to 159.76%.

  • InMed Pharmaceuticals' EBITDA Margin fell 2643.00% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.64%, marking a year-over-year decrease of 2127.00%. This contributed to the annual value of 159.76% for FY2025, which is 1747.00% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported EBITDA Margin of 159.76% as of FY2025, which was up 9.86% from 177.23% recorded in FY2024.
  • InMed Pharmaceuticals' EBITDA Margin's 5-year high stood at 159.76% during FY2025, with a 5-year trough of 1,707.32% in FY2022.
  • In the last 3 years, InMed Pharmaceuticals' EBITDA Margin had a median value of 177.23% in 2024 and averaged 179.93%.
  • In the last 5 years, InMed Pharmaceuticals' EBITDA Margin surged by 150,451bps in 2023 and then tumbled by 1,747bps in 2025.
  • InMed Pharmaceuticals' EBITDA Margin (MRY) stood at 1,707.32% in 2022, then soared by 88bps to 202.81% in 2023, then increased by 13bps to 177.23% in 2024, then rose by 10bps to 159.76% in 2025.
  • Its last three reported values are 159.76% in FY2025, 177.23% for FY2024, and 202.81% during FY2023.